---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349133"
form_type: "8-K"
ticker: "AKTS"
cik: "0002035832"
company_name: "Aktis Oncology, Inc."
filed_at: "2026-08-13T20:04:16+00:00"
generated_at: "2026-08-13T20:05:04.445659+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aktis Oncology Q2 net loss $24.1M; cash $517.3M funds operations into 2029

## Summary
- Net loss $24.1M for Q2 2026 vs $18.1M prior-year; interest income net of $4.8M.
- Cash, equivalents, marketable securities $517.3M at June 30, 2026 vs $226.8M Dec 31, 2025.
- Collaboration revenue $3.4M (Q2 2026) vs $1.6M prior-year, from Eli Lilly partnership.
- R&D expenses $25.3M, up from $18.6M; G&A $7.0M vs $3.9M year-over-year.
- Phase 1b trials: AKY-1189 (NECTINIUM-2) enrolling; AKY-2519 BActinium-2 to start H2 2026.

## SEC filing metadata
- accession: 0001193125-26-349133
- form_type: 8-K
- ticker: AKTS
- cik: 0002035832
- company_name: Aktis Oncology, Inc.
- filed_at: 2026-08-13T20:04:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/0001193125-26-349133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/ck0002035832-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349133
- JSON: https://secwatch.observer/filing/0001193125-26-349133.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.